Dtic-Dome

Drug Description

font size

WARNING

It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.

Hemopoietic depression is the most common toxicity with DTIC-Dome (See WARNINGS).
Hepatic necrosis has been reported (See WARNINGS).
Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals.
In treatment of each patient, the physician must weigh carefully the possibility of achieving therapeutic benefit against the risk of toxicity.

DRUG DESCRIPTION

DTIC-Dome Sterile (dacarbazine) is a colorless to an ivory colored solid which is light sensitive. Each vial contains 100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol. DTIC-Dome is reconstituted and administered intravenously (pH 3-4). DTIC-Dome is an anticancer agent. Chemically, DTIC-Dome is 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC) with the following structual formula: